Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients

What Was Tested

Researchers studied Octreotide and Somatostatin in the context of hyperparathyroidism in this clinical trial publication.

To evaluate the effects of depot long acting octreotide (OCT-LAR) in patients with MEN1-related PHP.

Who Took Part

By PubMed's age tags, the people studied were young adults, adults, middle-aged adults and older adults, both men and women.

Eight patients with a genetically confirmed MEN1, presenting both PHP and duodeno-pancreatic neuroendocrine tumours (NET), were enrolled.

Before OCT-LAR therapy, a SST scintigraphy was performed in all patients.

How the Study Was Run

This therapy was established to stabilize the duodeno-pancreatic NET before to perform parathyroidectomy for PHP.

SST subtype 2A immunohistochemistry was performed on parathyroid tumour samples from three patients undergone parathyroidectomy after OCT-LAR therapy.

Serum concentrations of PTH, calcium and phosphorus as well as the 24-h urine calcium : creatinine ratio and the renal threshold phosphate concentration were evaluated before and after OCT-LAR.

What Was Measured

Topics PubMed links to this paper include Antineoplastic Agents, Hormonal, Duodenal Neoplasms, Hyperparathyroidism, Primary, Multiple Endocrine Neoplasia Type 1, Neuroendocrine Tumors, Octreotide and Pancreatic Neoplasms.

What This Means in Plain Language

This is a clinical trial of Octreotide and Somatostatin in people with hyperparathyroidism.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Clinical endocrinology), a journal based in England.

More context: the Octreotide compound page and the Somatostatin compound page, Hyperparathyroidism research.